DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 12-516/S-038/S-041/S-045

Novartis Pharmaceuticals Corporation
Attention: Kay A. Chitale, Pharm.D.
Drug Regulatory Affairs
59 Route 10
East Hanover, NJ 07936-1080

Dear Dr. Chitale:

Please refer to your supplemental new drug applications dated April 5, 1991 (S-038), March 31, 1995 (S-041), and April 7, 1997 (S-045), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Sansert (methysergide maleate) 2 mg Tablets.

These "Changes Being Effected" supplemental new drug applications provide for the following revisions to product labeling:

**12-516/S-038**
The supplement provides for the revision of the **DESCRIPTION** section to update this section of labeling.

**12-516/S-041**
The supplement provides for revisions to add new safety information primarily derived from the Novartis safety database. The specific revisions are as follows:

1. The addition of hypersensitivity to Sansert or any of its components under the **CONTRAINDICATIONS** section.
2. The addition of a new subsection entitled **Information for Patients** which duplicates information previously conveyed under the **WARNINGS** and **DOSAGE AND ADMINISTRATION** sections.
3. The addition of new subsections entitled **Drug Interactions**, **Pregnancy Category X**, **Nursing Mothers**, and **Pediatric Use** in the **PRECAUTIONS** section.
4. The addition of several adverse event terms to the **ADVERSE REACTIONS** section.
5. A new section entitled **OVERDOSAGE**.

**12-516/S-045**
This supplemental application provides for labeling changes to comply with the Final Rule regarding pediatric labeling. The specific changes are as follows:

1. The addition of the terms pregnancy and lactation to the **CONTRAINDICATIONS** section.
2. A statement regarding concurrent use with vasoconstrictive agents under the **PRECAUTIONS-Drug Interactions** section.
3. An update to the **PRECAUTIONS-Pediatric Use** section.
4. An update to the **OVERDOSAGE** section.

We have completed the review of these supplemental applications (NDA 12-516/S-038/S-041/S-045) and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert submitted April 7, 1997/Label Code 30186903), which incorporates all of the revisions listed. Accordingly, these supplemental applications are approved effective on the date of this letter.

Labeling changes of the kind which you have proposed under the above supplemental applications are permitted by section 314.70(c) of the regulations to be instituted prior to approval of the supplement. It is understood that the changes, described in the above NDA supplements, have been made.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Ms. Lana Chen, R.Ph., Regulatory Project Manager, at (301) 594-2850.

Sincerely,

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research